Glucagon

Glucagon occupies an unusual position in the peptide-pharmacology landscape: it is simultaneously a classical FDA-approved emergency rescue medication, the historical reference molecule for endocrine counter-regulation, and the third receptor in the most aggressive obesity-pharmacotherapy candidates currently in late-stage development.

The clinical history begins in 1923, three years after the discovery of insulin, when Charles Kimball and John Murlin identified a hyperglycemic contaminant in early insulin preparations and named it "glucagon" — the glucose-agonist. Recombinant glucagon entered clinical use as a hypoglycemia rescue agent in the 1960s; until 2019, the standard product was a lyophilized powder requiring on-site reconstitution before intramuscular or subcutaneous injection, with predictable real-world failure rates when a frightened bystander attempted the multi-step procedure under stress.

Three modern formulations transformed the rescue category between 2019 and 2021. Baqsimi (Eli Lilly) received FDA approval on July 24, 2019, as the first intranasal glucagon — a single 3-mg dose delivered via a small disposable device, no reconstitution, FDA-approved for severe hypoglycemia in patients aged four and older. Gvoke (Xeris Pharmaceuticals) received FDA approval on September 10, 2019, as the first ready-to-use stable liquid glucagon, available as a prefilled syringe or auto-injector (HypoPen), approved for ages two and older. Zegalogue (Zealand Pharma) received FDA approval on March 22, 2021, as the first glucagon analog — dasiglucagon, a stable-in-solution engineered variant with a median time to blood glucose recovery of approximately 10 minutes (Blair, Drugs 2021, 81:1115–1120), approved for ages six and older. The current American Diabetes Association Standards of Care position is that all individuals on insulin or at elevated hypoglycemia risk should be prescribed glucagon, with the intranasal and ready-to-inject preparations preferred over older lyophilized kits on ease-of-administration grounds.

A second classical indication — and one that occasionally surfaces in adjacent clinical literature — is glucagon as a diagnostic aid in gastrointestinal radiology and endoscopy, where its smooth-muscle relaxant effect on the GI tract reduces motility and improves visualization during barium studies, ERCP, and similar procedures. The motility use is mechanistically distinct from the hyperglycemic rescue use; it is a side effect of glucagon-receptor activity on GI smooth muscle and has been a labeled FDA indication for decades. A historical diagnostic use — the glucagon stimulation test for growth hormone deficiency and pituitary-adrenal axis evaluation — remains in use as a second-line provocative test in pediatric endocrinology. Native glucagon is contraindicated in patients with insulinoma (it can trigger paradoxical insulin release and severe rebound hypoglycemia) and in pheochromocytoma (it stimulates catecholamine release from chromaffin-cell tumors); these contraindications appear on every glucagon product label.

The reason glucagon belongs on this site, however, is the third use case — the one that is not approved, that is the foundation of an entire class of investigational obesity drugs, and that is genuinely counter-intuitive given the rescue-medication framing. The pharmacology that raises blood glucose acutely is the same pharmacology that — in chronic, balanced, sub-hyperglycemic dosing combined with GLP-1 agonism — drives weight loss through increased energy expenditure and lipid oxidation. The mechanistic case was developed across the 2000s; the proof-of-concept paper is Day et al., Nat Chem Biol 2009, 5:749–757, which demonstrated that a chemically modified GLP-1/glucagon co-agonist administered to diet-induced obese mice normalized adiposity and glucose tolerance — weight reduction driven by both decreased food intake (the GLP-1 contribution) and increased energy expenditure (the glucagon contribution), with no hyperglycemia at the doses studied. The Habegger 2010 review consolidated the framing: glucagon's hypolipidemic, energy-expenditure-stimulating, and satiating effects make it a candidate component of obesity pharmacotherapy when paired with mechanisms that suppress the hyperglycemic effect.

This concept reached clinical proof in retatrutide, the triple GIP / GLP-1 / glucagon agonist whose Phase 2 trial produced mean weight loss of 24.2% at 48 weeks on the 12-mg dose — exceeding the magnitude observed with tirzepatide (dual GIP / GLP-1, no glucagon component) in the SURMOUNT-1 trial and with semaglutide (GLP-1 only) in STEP 1, and approaching the response envelope previously confined to bariatric surgery. Survodutide, a GLP-1 / glucagon dual agonist co-invented by Boehringer Ingelheim and Zealand Pharma, reached approximately 19% weight loss on the 4.8-mg dose in its Phase 2 program and produced 17.8 kg mean loss at 76 weeks in the SYNCHRONIZE-1 Phase 3 readout. The GLP-1 receptor pharmacology dossier walks the receptor-engagement breadth story across the modern obesity-pharmacotherapy landscape; the hepatic fat decision guide and the fat-loss decision guide cover the applied positioning.

A common source of reader confusion is the relationship between glucagon and glucagon-like peptide-1 (GLP-1). Despite the naming, the two are distinct molecules acting on distinct receptors — both derived from the same proglucagon precursor through tissue-specific post-translational processing (pancreatic α-cells produce glucagon; intestinal L-cells produce GLP-1). Glucagon raises blood glucose; GLP-1 lowers blood glucose by stimulating glucose-dependent insulin secretion. The triple-agonist drugs that engage both receptors are leveraging the opposing glycemic effects against each other while preserving the shared lipid-mobilization and central-appetite-suppressive signals. The pharmacology is genuinely complex and is the active mechanistic question that decades of single-receptor work has finally opened.

The honest framing has three parts. First, native glucagon is well-characterized, FDA-approved, and not a gray-market peptide — the rescue formulations are standard endocrinology pharmacy stock and the application is narrow, acute, and uncontroversial. Second, the glucagon-receptor agonism inside the triple-agonist class is the same receptor used in reverse — chronic, balanced, low-grade — and the long-term safety story of that chronic dosing pattern is genuinely new and not yet mature, even though the acute pharmacology is well-trodden. Third, glucagon itself is not a body-composition tool. The pharmacology that matters for weight loss is the engineered agonism inside retatrutide, survodutide, and the next-generation candidates behind them — not the rescue kit in a diabetic patient's medicine cabinet.